Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis
about
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsXpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsRapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysisThe impact and cost of scaling up GeneXpert MTB/RIF in South AfricaPopulation health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluationThe biology of mycobacterium tuberculosis infection.Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysisSpeed and convenience aren't everything with diagnostics.Modeling of novel diagnostic strategies for active tuberculosis - a systematic review: current practices and recommendations.Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries.Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. a hypothetical trial.How methodologic differences affect results of economic analyses: a systematic review of interferon gamma release assays for the diagnosis of LTBIPulmonary tuberculosis incidence and risk factors in rural areas of China: a cohort studyGeneXpert--a game-changer for tuberculosis control?The Application of GeneXpert MTB/RIF for Smear-Negative TB Diagnosis as a Fee-Paying Service at a South Asian General Hospital.Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients' experiences in the era of rapid molecular diagnostic tests.Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis.Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics.Rapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF?The impact of new tuberculosis diagnostics on transmission: why context matters.The ethics of testing a test: randomized trials of the health impact of diagnostic tests for infectious diseases.Multicenter Evaluation of Anyplex Plus MTB/NTM MDR-TB Assay for Rapid Detection of Mycobacterium tuberculosis Complex and Multidrug-Resistant Isolates in Pulmonary and Extrapulmonary SpecimensChallenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis.Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.Economic evaluations of point of care testing strategies for active tuberculosis.A guide to aid the selection of diagnostic tests.GeneXpert in the diagnosis of smear-negative PTB.Editorial Comment: Cost-Effectiveness Analysis for Prioritization of Limited Public Health Resources - Tuberculosis Interventions in Texas.Evidence supports TB test, so what now?Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics.Mass Spectrometric Identification of Urinary Biomarkers of Pulmonary Tuberculosis.
P2860
Q24200879-D726BB7E-F5B8-401A-9E9D-E90BA1B315BCQ24201466-47BF9BFB-159A-461A-B91E-D2439BAEA6A8Q28477855-8DCD07BA-0102-4D30-BEA7-36EA14A8BD77Q28484044-8AFFDD1E-0312-4498-9F34-58D4F9422668Q28485280-E5AF7F2B-91CC-42FC-B866-BF99AF05342CQ30357155-B687766B-FE28-45AA-993A-7343717F5B91Q30566518-8839695E-DF9D-4EDC-AE07-5523427F0304Q33924814-2247CFDA-474C-4F22-920F-1389A2A12C84Q33998704-91C0082E-95DF-494D-9CD4-EB69A3E23438Q34062149-19D7EBDA-7F0C-4D30-B6DB-CF6BCB356617Q34395434-2C438026-BEE0-4E51-BA3A-E82A9E989A19Q34413592-2404E899-F19B-4CDE-A736-FA0D6536D1A7Q34480176-CF4A2903-4E0B-47BD-BFC2-1C0CC049224CQ34625452-C90879BE-A89A-4F69-AE29-222C179425D5Q34647944-8B3F9962-B9C0-4EA7-96E9-B096C7D769B3Q35129500-516CC923-E275-4AC6-B2DE-FFADE22866D2Q35531476-54CDD22B-939B-4667-936D-C24C5F9796D3Q35825395-559CD272-12F6-4454-9151-2BCFDCF8D520Q35907384-2A12D4D7-323F-4F7F-8040-50CA272F318CQ36066438-6C0140F5-2A8E-46F3-9AB2-179773C4FE74Q36149564-F136F3F4-ADFE-4665-A4D3-91E3B1FE70ACQ36316501-7F08D5CA-8B1D-43B4-A555-F3627C7040F6Q36379606-2D696D22-0CB0-409A-81C0-20F38FD4409BQ36434491-30CFF0B9-E396-489D-9FF4-EB54F84839E7Q37151512-5DBE9AF3-C1BB-45A8-8907-EBE67CC9EBCEQ38002002-52214E64-057E-492D-8700-7B25997E005DQ38114142-8C644774-BA4D-4801-AB39-2E55F30BC1ECQ41575780-1B0CF0B0-CCC6-42A3-96E8-850940EF6F92Q41896188-082C4A0F-8282-4284-8AE4-CDFFCF8792A9Q41955733-B6AAABB7-07C3-4C85-848A-9F0BF181910BQ46777871-29725AF2-36E5-4DC1-91D5-E3BEC3FE883EQ49332222-1D4D55EB-AF2A-43AF-A9AB-A7A7929F2E3BQ53719641-249DD610-9061-41BA-9E00-3D555D568229
P2860
Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Is scale-up worth it? Challeng ...... gnostic tests for tuberculosis
@ast
Is scale-up worth it? Challeng ...... gnostic tests for tuberculosis
@en
type
label
Is scale-up worth it? Challeng ...... gnostic tests for tuberculosis
@ast
Is scale-up worth it? Challeng ...... gnostic tests for tuberculosis
@en
prefLabel
Is scale-up worth it? Challeng ...... gnostic tests for tuberculosis
@ast
Is scale-up worth it? Challeng ...... gnostic tests for tuberculosis
@en
P2860
P1433
P1476
Is scale-up worth it? Challeng ...... gnostic tests for tuberculosis
@en
P2093
Adithya Cattamanchi
David W Dowdy
P2860
P304
P356
10.1371/JOURNAL.PMED.1001063
P407
P577
2011-07-26T00:00:00Z